LNP SOLUTION, LTD.

LNP SOLUTION, LTD. , based in South Korea, specializes in advanced in-silico services utilizing molecular modeling and artificial intelligence to enhance drug development processes for various clients in the pharmaceutical sector. Founded in 2022, LNP Solution focuses on providing in-silico services that support drug development. The company has not undergone any notable pivots or changes in its business operations.

LNP Solution does not have any known subsidiaries or parent companies. It was established to cater to the growing demand for advanced molecular modeling solutions. The founder's background is not publicly detailed. The firm has completed 1 deal, with its most recent deal occurring on September 19, 2025.

LNP Solution specializes in providing innovative in-silico services that leverage advanced molecular modeling simulations and artificial intelligence technologies to support early drug development stages. Their primary offerings include state-of-the-art molecular modeling software, notably the Schrödinger platform, aimed at enhancing molecular design and discovery processes. The company serves a diverse clientele, including universities, biopharmaceutical companies, and government institutions, primarily in South Korea, focusing on improving research efficiency and productivity through their AI-driven molecular simulations. LNP Solution operates on a B2B model, generating revenue primarily through service contracts and software licenses.

Clients engage LNP Solution for specific projects or ongoing partnerships, often involving customized agreements for molecular dynamics simulations, virtual screening, and other CRO services tailored to their research needs. The company is positioned to support organizations seeking high-quality assistance in drug discovery, contributing significantly to the biopharmaceutical industry's development. LNP SOLUTION, LTD. plans to utilize the undisclosed amount raised in Seed funding from CNT Tech and AI Angel Club in September 2025 to enhance collaboration with domestic and international pharmaceutical companies and to advance its artificial intelligence-based drug development technology.

The company aims to expand its reach into new markets and geographic regions, although specific details regarding these regions or product launches have not been disclosed.